1300 South El Camino Real
Suite 400
San Mateo, CA 94402
United States
(650) 781-5200
https://www.kronosbio.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 61
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Dr. Norbert W. Bischofberger Ph.D. | President, CEO & Director | 912,2k | N/A | 1956 |
Mr. Joshua A. Kazam | Co-Founder & Director | 40k | N/A | 1977 |
Mr. David M. Tanen J.D. | Secretary & Director | 40k | N/A | 1971 |
Dr. Deborah A. Knobelman Ph.D. | COO & CFO | N/A | N/A | 1974 |
Dr. Margaux Bennett Ph.D. | Vice President of Corporate Development & Investor Relations | N/A | N/A | N/A |
Ms. Allison Frisbee J.D. | Senior Vice President of Corporate Operations & Legal | N/A | N/A | 1983 |
Dr. Charles Lin Ph.D. | Senior Vice President of Research & Development | N/A | N/A | 1985 |
Dr. Elizabeth A. Olek D.O., M.P.H. | Senior Vice President of Clinical Development | N/A | N/A | 1965 |
Mr. Wes Trotter Ph.D. | Senior Vice President of Drug Discovery & Pharmaceutical Development | N/A | N/A | N/A |
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.
Kronos Bio, Inc.s ISS Governance QualityScore, Stand 1. Juni 2024, lautet 9. Die grundlegenden Scores sind Audit: 9, Vorstand: 10, Shareholderrechte: 8, Kompensation: 8.